Cure51
Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus for Cure51 is initially to start with 3 types of particularly agressive cancers and will naturally expand to other indications and therapeutic areas to capitalize on its exclusive and unprecedented set of data and discovery pipelines.
Cure51
Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus for Cure51 is initially to start with 3 types of particularly agressive cancers and will naturally expand to other indications and therapeutic areas to capitalize on its exclusive and unprecedented set of data and discovery pipelines.
TL;DR
What they do: Build a global multi-omics database of exceptional long-term cancer survivors to discover therapeutic targets
Headquarters / base: Paris, France
Founded: 2022
Latest funding: €15M seed (Mar 2024) led by Sofinnova Partners
Scale: ~50 employees
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Oncology drug discovery using multi-omics and survivor-derived biological insights
Founded
2022
Industry
Biotechnology Research
Funding Track Record
€15 million
Participants included Hitachi Ventures, Life Extension Ventures, Xavier Niel and Olivier Pomel
Investor Signal
“Backed by healthcare and life-sciences investors including Sofinnova Partners and corporate VC participation”